Omeros Q2 net loss narrows to $25.4M; narsoplimab PDUFA extended to Dec 2025; debt reduced by $80M

OMEROS CORP

2025-Q2 EPS reported -$1.01 vs consensus -$0.49 ▼ miss (-105.9%)

Net loss of $25.4M ($0.43/sh) vs $56.0M ($0.97/sh) a year ago; cash, short-term investments $28.7M at June 30.
Post-quarter: raised $20.6M net from Polar Asset Management (5.37M shares at $4.10, 14% premium) plus $2.1M from ATM.
Narsoplimab BLA PDUFA date extended to Dec 26, 2025; FDA expects labeling talks by Oct. EMA MAA validated, opinion mid-2026.
Exchanged $70.8M of 2026 Notes for 2029 Notes; remaining 2026 Notes reduced to $17.1M; avoided $20M prepayment on term debt.
In talks for potential asset deal with multi-billion total value; upfront cash would repay $67.1M term loan and $17.1M notes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.